Syrrx forms alliance with Novartis Research Foundation
Under the terms of the agreement, Syrrx has been granted an exclusive license to GNF tools used for cloning, protein expression, protein purification, protein crystallization and a collection of X-ray diffraction data for use within structural proteomics.
GNF will take a minority equity position in Syrrx and a seat on the company's board of directors.
The collaboration will focus initially on high-throughput technologies for fermentation protein purification robotics and protein crystallization systems.
GNF and Syrrx share a similar approach to the industrialization of the protein structure determination process, said Peter Schultz, Director of GNF. This collaboration will have long-term benefits for Syrrx, GNF, and the scientific community.
This collaboration will enable our two organizations to combine our knowledge of biochemistry, computational biology, and engineering to reach goals efficiently, said Wendell Wierenga, CEO of Syrrx.